AI leadership is beginning to fracture, but the weakness is creating opportunities beyond the market's most crowded trades. This week's screen identified five stocks across financial infrastructure, North American transportation, travel, biotechnology and specialized consulting, with extended targets offering roughly 6% to 12% upside and closing stops generally limited to 2% to 4%. One selection has the cleanest risk-reward profile in the group, two maintain bullish short-term moving-average structures, and one small-cap setup could rerate quickly if its post-earnings base resolves higher. Each pick includes an entry condition, target and invalidation level, making the list actionable even if the S&P 500 remains volatile. For transparency, last week's equal-weight basket declined about 4% versus 0.5% for the S&P 500; BRK.B was the best relative performer at roughly -2%, NVO remained above its stop, and closing stops removed the four setups that failed to maintain momentum.
This Week's Best Setup: Canadian Pacific Kansas City
CP offers the cleanest trend and strongest immediate risk-reward profile. A partial position can be considered while the stock holds $92–$92.50, with additional exposure reserved for a confirmed breakout above $94.70. The targets are $99 and $102, offering roughly 6% to 9% upside, while the $91.50 closing stop limits indicated downside to approximately 2%.
The percentages below are calculated from the latest closing prices and rounded for readability.
Canadian Pacific Kansas City (CP)
Large cap — approximately $82.4 billion
Strength: CPKC owns an infrastructure advantage that competitors cannot easily reproduce: the only single-line railway connecting Canada, the United States and Mexico. Its network provides exposure to cross-border manufacturing, agricultural exports, automotive supply chains and the gradual relocation of production closer to North American consumers.
The catalyst is not simply higher freight volumes. CPKC can move cargo across three countries without many of the delays and handoffs required when several railway operators are involved. As the integration matures, the company can win more complex routes and extract additional commercial benefits from the combined network. Trade policy and fuel prices remain risks, but the railway's strategic value should become more visible as manufacturers prioritize reliable North American supply chains.
Technical: CP has the cleanest trend alignment among the five selections. MA3 remains above MA7 and MA10, while the intermediate-term averages are also rising. Resistance is concentrated around $94.50–$94.70. A confirmed move through that zone would complete the next breakout. If the breakout is delayed, the $92–$92.50 area should act as initial support.
Short-term target: $99 initially, offering approximately 6% upside. An extended move could reach $102, representing roughly 9% upside.
Stop loss: A close below $91.50, approximately 2% downside. That would invalidate the recent higher-low structure.
CME Group (CME)
Large cap — approximately $97.6 billion
Strength: CME is one of the rare businesses for which uncertainty is a source of demand rather than simply a risk. Disagreement over interest rates, energy prices, currencies, commodity supply and equity valuations increases the need for futures and options, allowing CME to participate without predicting which direction those markets ultimately move.
Recent activity has strengthened across interest rates, equity indexes, energy, agriculture and metals, while international participation continues expanding. That breadth reduces dependence on any single contract category. CME also provides diversification because it is not another directional bet on AI spending or consumer confidence; it benefits when investors need to manage uncertainty across multiple markets.
Technical: CME maintains a bullish short-term structure, with MA3 above MA7 and MA10. The next confirmation zone is around $274, although the 200-day moving average near $278–$280 remains an important obstacle. A controlled pullback that holds $267–$269 could provide an alternative entry.
The $280 level should be viewed as a resistance checkpoint rather than the complete target. A successful move through the 200-day average would create the stronger risk-reward opportunity.
Short-term target: $280 initially, offering roughly 3% upside. The primary extended target is $288, representing approximately 6% upside.
Stop loss: A close below $264.50, approximately 3% downside. That would break the short-term moving-average structure.
Vertex Pharmaceuticals (VRTX)
Large cap — approximately $133.9 billion
Strength: Vertex is evolving from a company valued mainly for its cystic-fibrosis franchise into a broader commercial-stage biotechnology platform. The existing franchise supplies the cash needed to fund expansion, while JOURNAVX gives Vertex a credible entry into the non-opioid pain market.
The larger rerating opportunity comes from its developing positions in kidney disease, gene editing, blood disorders and potentially endocrinology through the pending Crinetics acquisition. Povetacicept has an upcoming FDA decision and, if approved, would establish Vertex's first commercial kidney-disease franchise. These programs reduce long-term dependence on cystic fibrosis and create several catalysts that are not tied directly to the economic cycle.
Technical: VRTX has recovered from its latest pullback and returned above MA3, MA7 and MA10. MA3 has not yet established a decisive lead over MA7, so the recovery is improving but not fully confirmed.
The first confirmation level is around $534. A sustained move above that zone would open another test of resistance near $546. The $515–$520 area should act as initial support. Investors should wait for either breakout confirmation or a successful test of that support range.
Short-term target: $548 initially, offering approximately 4% upside. Clearing the prior resistance zone could extend the move toward $570, representing roughly 8% upside.
Stop loss: A close below $511, approximately 3% downside. That would erase the latest recovery structure.
Airbnb (ABNB)
Large cap — approximately $108.0 billion
Strength: Airbnb's next stage is less about adding another rental listing and more about becoming a broader travel platform. Services, local experiences, boutique hotels, transportation partnerships and AI-powered trip planning could increase the number of transactions attached to each journey.
Boutique hotels can capture trips for which a private home is not the preferred option, while experiences and services address spending that previously occurred outside the platform. AI can improve search, itinerary planning and customer support, potentially making the service more reliable while lowering operating costs. Exclusive World Cup experiences and the summer product expansion provide an opportunity to prove that these categories can become meaningful growth engines.
Technical: ABNB is consolidating after a powerful upside move. MA3 and MA7 remain close together but are comfortably above MA10, suggesting that the stock is digesting gains rather than immediately breaking down.
Resistance sits around $186–$187. A confirmed breakout above $187.20 would indicate that buyers are ready to begin another leg higher. Alternatively, a pullback that holds $179–$181 could provide a more attractive entry. Because the initial rerating has already been substantial, the stock should not be chased directly below resistance.
Short-term target: $198 initially, offering approximately 8% upside. Continued momentum could extend the move toward $205, representing roughly 12% upside.
Stop loss: A close below $177.50, approximately 3% downside. That would break MA10 and the current consolidation.
Huron Consulting Group (HURN)
Small cap — approximately $2.25 billion
Strength: Huron is the higher-risk selection, but it offers a differentiated small-cap growth story. Hospitals and universities face persistent pressure to reduce costs, modernize outdated systems and improve efficiency. Those problems are difficult to postpone, creating demand for Huron's consulting, digital-transformation and managed-services capabilities.
Huron can also turn AI into a practical service rather than selling an abstract technology narrative. Its industry knowledge and implementation experience can help healthcare and education clients integrate automation into real operating processes. Strong demand, an expanding backlog and higher full-year expectations support the thesis, while share repurchases could increase the per-share benefit if operating momentum continues.
Technical: HURN experienced a major post-earnings rerating and has since been building a new base. Its short-term averages are tightly compressed rather than fully bullish, so this remains a developing breakout opportunity.
Resistance is concentrated around $155.50–$157. A confirmed move above $157 would indicate that buyers are regaining control. Support sits around $146, followed by a deeper zone near $143. Because the post-earnings range remains volatile, HURN should be the only speculative position and should be traded at a smaller size.
Short-term target: $163 initially, offering approximately 8% upside. A successful move through that level could extend toward $170, representing roughly 12% upside.
Stop loss: A close below $145.50, approximately 4% downside. That would break the developing base.
Priority Ranking
1. Canadian Pacific Kansas City: Best overall risk-reward profile and the cleanest trend.
2. CME Group: Strong relative strength and a business model that benefits from uncertainty.
3. Vertex Pharmaceuticals: The strongest company-specific catalyst pipeline, but resistance must be cleared.
4. Airbnb: The strongest raw momentum and up to 12% extended upside, balanced by greater entry-timing risk.
5. Huron Consulting: The most interesting small-cap rerating opportunity, but also the least-confirmed and highest-risk setup.
For investors selecting only one position, CP offers the strongest balance of trend quality, upside potential and downside control. A two-stock combination of CP and CME provides exposure to independent catalysts without relying on the same technology or consumer theme.
All stop losses are based on closing prices. A stock that has not activated its entry condition remains on the watchlist, while a close beneath the stated stop invalidates the setup.
Read full article here »
View the Zacks #1 Rank List
The Market's Most Crowded Trade Is Cracking—Watch 5 Stocks Showing Strength Beneath the Selloff
AI leadership is beginning to fracture, but the weakness is creating opportunities beyond the market's most crowded trades. This week's screen identified five stocks across financial infrastructure, North American transportation, travel, biotechnology and specialized consulting, with extended targets offering roughly 6% to 12% upside and closing stops generally limited to 2% to 4%. One selection has the cleanest risk-reward profile in the group, two maintain bullish short-term moving-average structures, and one small-cap setup could rerate quickly if its post-earnings base resolves higher. Each pick includes an entry condition, target and invalidation level, making the list actionable even if the S&P 500 remains volatile. For transparency, last week's equal-weight basket declined about 4% versus 0.5% for the S&P 500; BRK.B was the best relative performer at roughly -2%, NVO remained above its stop, and closing stops removed the four setups that failed to maintain momentum.
This Week's Best Setup: Canadian Pacific Kansas City
CP offers the cleanest trend and strongest immediate risk-reward profile. A partial position can be considered while the stock holds $92–$92.50, with additional exposure reserved for a confirmed breakout above $94.70. The targets are $99 and $102, offering roughly 6% to 9% upside, while the $91.50 closing stop limits indicated downside to approximately 2%.
The percentages below are calculated from the latest closing prices and rounded for readability.
Canadian Pacific Kansas City (CP)
Large cap — approximately $82.4 billion
Strength: CPKC owns an infrastructure advantage that competitors cannot easily reproduce: the only single-line railway connecting Canada, the United States and Mexico. Its network provides exposure to cross-border manufacturing, agricultural exports, automotive supply chains and the gradual relocation of production closer to North American consumers.
The catalyst is not simply higher freight volumes. CPKC can move cargo across three countries without many of the delays and handoffs required when several railway operators are involved. As the integration matures, the company can win more complex routes and extract additional commercial benefits from the combined network. Trade policy and fuel prices remain risks, but the railway's strategic value should become more visible as manufacturers prioritize reliable North American supply chains.
Technical: CP has the cleanest trend alignment among the five selections. MA3 remains above MA7 and MA10, while the intermediate-term averages are also rising. Resistance is concentrated around $94.50–$94.70. A confirmed move through that zone would complete the next breakout. If the breakout is delayed, the $92–$92.50 area should act as initial support.
Short-term target: $99 initially, offering approximately 6% upside. An extended move could reach $102, representing roughly 9% upside.
Stop loss: A close below $91.50, approximately 2% downside. That would invalidate the recent higher-low structure.
CME Group (CME)
Large cap — approximately $97.6 billion
Strength: CME is one of the rare businesses for which uncertainty is a source of demand rather than simply a risk. Disagreement over interest rates, energy prices, currencies, commodity supply and equity valuations increases the need for futures and options, allowing CME to participate without predicting which direction those markets ultimately move.
Recent activity has strengthened across interest rates, equity indexes, energy, agriculture and metals, while international participation continues expanding. That breadth reduces dependence on any single contract category. CME also provides diversification because it is not another directional bet on AI spending or consumer confidence; it benefits when investors need to manage uncertainty across multiple markets.
Technical: CME maintains a bullish short-term structure, with MA3 above MA7 and MA10. The next confirmation zone is around $274, although the 200-day moving average near $278–$280 remains an important obstacle. A controlled pullback that holds $267–$269 could provide an alternative entry.
The $280 level should be viewed as a resistance checkpoint rather than the complete target. A successful move through the 200-day average would create the stronger risk-reward opportunity.
Short-term target: $280 initially, offering roughly 3% upside. The primary extended target is $288, representing approximately 6% upside.
Stop loss: A close below $264.50, approximately 3% downside. That would break the short-term moving-average structure.
Vertex Pharmaceuticals (VRTX)
Large cap — approximately $133.9 billion
Strength: Vertex is evolving from a company valued mainly for its cystic-fibrosis franchise into a broader commercial-stage biotechnology platform. The existing franchise supplies the cash needed to fund expansion, while JOURNAVX gives Vertex a credible entry into the non-opioid pain market.
The larger rerating opportunity comes from its developing positions in kidney disease, gene editing, blood disorders and potentially endocrinology through the pending Crinetics acquisition. Povetacicept has an upcoming FDA decision and, if approved, would establish Vertex's first commercial kidney-disease franchise. These programs reduce long-term dependence on cystic fibrosis and create several catalysts that are not tied directly to the economic cycle.
Technical: VRTX has recovered from its latest pullback and returned above MA3, MA7 and MA10. MA3 has not yet established a decisive lead over MA7, so the recovery is improving but not fully confirmed.
The first confirmation level is around $534. A sustained move above that zone would open another test of resistance near $546. The $515–$520 area should act as initial support. Investors should wait for either breakout confirmation or a successful test of that support range.
Short-term target: $548 initially, offering approximately 4% upside. Clearing the prior resistance zone could extend the move toward $570, representing roughly 8% upside.
Stop loss: A close below $511, approximately 3% downside. That would erase the latest recovery structure.
Airbnb (ABNB)
Large cap — approximately $108.0 billion
Strength: Airbnb's next stage is less about adding another rental listing and more about becoming a broader travel platform. Services, local experiences, boutique hotels, transportation partnerships and AI-powered trip planning could increase the number of transactions attached to each journey.
Boutique hotels can capture trips for which a private home is not the preferred option, while experiences and services address spending that previously occurred outside the platform. AI can improve search, itinerary planning and customer support, potentially making the service more reliable while lowering operating costs. Exclusive World Cup experiences and the summer product expansion provide an opportunity to prove that these categories can become meaningful growth engines.
Technical: ABNB is consolidating after a powerful upside move. MA3 and MA7 remain close together but are comfortably above MA10, suggesting that the stock is digesting gains rather than immediately breaking down.
Resistance sits around $186–$187. A confirmed breakout above $187.20 would indicate that buyers are ready to begin another leg higher. Alternatively, a pullback that holds $179–$181 could provide a more attractive entry. Because the initial rerating has already been substantial, the stock should not be chased directly below resistance.
Short-term target: $198 initially, offering approximately 8% upside. Continued momentum could extend the move toward $205, representing roughly 12% upside.
Stop loss: A close below $177.50, approximately 3% downside. That would break MA10 and the current consolidation.
Huron Consulting Group (HURN)
Small cap — approximately $2.25 billion
Strength: Huron is the higher-risk selection, but it offers a differentiated small-cap growth story. Hospitals and universities face persistent pressure to reduce costs, modernize outdated systems and improve efficiency. Those problems are difficult to postpone, creating demand for Huron's consulting, digital-transformation and managed-services capabilities.
Huron can also turn AI into a practical service rather than selling an abstract technology narrative. Its industry knowledge and implementation experience can help healthcare and education clients integrate automation into real operating processes. Strong demand, an expanding backlog and higher full-year expectations support the thesis, while share repurchases could increase the per-share benefit if operating momentum continues.
Technical: HURN experienced a major post-earnings rerating and has since been building a new base. Its short-term averages are tightly compressed rather than fully bullish, so this remains a developing breakout opportunity.
Resistance is concentrated around $155.50–$157. A confirmed move above $157 would indicate that buyers are regaining control. Support sits around $146, followed by a deeper zone near $143. Because the post-earnings range remains volatile, HURN should be the only speculative position and should be traded at a smaller size.
Short-term target: $163 initially, offering approximately 8% upside. A successful move through that level could extend toward $170, representing roughly 12% upside.
Stop loss: A close below $145.50, approximately 4% downside. That would break the developing base.
Priority Ranking
1. Canadian Pacific Kansas City: Best overall risk-reward profile and the cleanest trend.
2. CME Group: Strong relative strength and a business model that benefits from uncertainty.
3. Vertex Pharmaceuticals: The strongest company-specific catalyst pipeline, but resistance must be cleared.
4. Airbnb: The strongest raw momentum and up to 12% extended upside, balanced by greater entry-timing risk.
5. Huron Consulting: The most interesting small-cap rerating opportunity, but also the least-confirmed and highest-risk setup.
For investors selecting only one position, CP offers the strongest balance of trend quality, upside potential and downside control. A two-stock combination of CP and CME provides exposure to independent catalysts without relying on the same technology or consumer theme.
All stop losses are based on closing prices. A stock that has not activated its entry condition remains on the watchlist, while a close beneath the stated stop invalidates the setup.
Read full article here »